PH26554A - Inhibitory agent of hepatic fibrosis - Google Patents

Inhibitory agent of hepatic fibrosis Download PDF

Info

Publication number: PH26554A
Authority: PH; Philippines
Prior art keywords: fibrosis; pantethine; hepatic; hepatic fibrosis; inhibitory agent
Prior art date: 1988-01-06

Application number

PH38005A

Other languages

English (en)

Inventor

Munehiro Tomikawa

Junichiro Wakasugi

Original Assignee

Daiichi Seiyaku Co

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

1988-01-06

Filing date

1989-01-05

Publication date

1992-08-19

1989-01-05 Application filed by Daiichi Seiyaku Co filed Critical Daiichi Seiyaku Co

1992-08-19 Publication of PH26554A publication Critical patent/PH26554A/en

Links

206010019668 Hepatic fibrosis Diseases 0.000 title claims description 9
230000002401 inhibitory effect Effects 0.000 title claims description 9
DJWYOLJPSHDSAL-UHFFFAOYSA-N Pantethine Natural products OCC(C)(C)C(O)C(=O)NCCC(=O)NCCSSCCNC(=O)CCNC(=O)C(O)C(C)(C)CO DJWYOLJPSHDSAL-UHFFFAOYSA-N 0.000 claims description 11
DJWYOLJPSHDSAL-ROUUACIJSA-N pantethine Chemical compound OCC(C)(C)[C@@H](O)C(=O)NCCC(=O)NCCSSCCNC(=O)CCNC(=O)[C@H](O)C(C)(C)CO DJWYOLJPSHDSAL-ROUUACIJSA-N 0.000 claims description 11
229960000903 pantethine Drugs 0.000 claims description 11
235000008975 pantethine Nutrition 0.000 claims description 11
239000011581 pantethine Substances 0.000 claims description 11
206010016654 Fibrosis Diseases 0.000 claims description 9
230000004761 fibrosis Effects 0.000 claims description 8
HVYWMOMLDIMFJA-DPAQBDIFSA-N cholesterol Chemical compound C1C=C2C[C@@H](O)CC[C@]2(C)[C@@H]2[C@@H]1[C@@H]1CC[C@H]([C@H](C)CCCC(C)C)[C@@]1(C)CC2 HVYWMOMLDIMFJA-DPAQBDIFSA-N 0.000 description 9
230000000694 effects Effects 0.000 description 6
230000002440 hepatic effect Effects 0.000 description 6
210000004185 liver Anatomy 0.000 description 6
102000004079 Prolyl Hydroxylases Human genes 0.000 description 5
108010043005 Prolyl Hydroxylases Proteins 0.000 description 5
102000008186 Collagen Human genes 0.000 description 4
108010035532 Collagen Proteins 0.000 description 4
229940107161 cholesterol Drugs 0.000 description 4
235000012000 cholesterol Nutrition 0.000 description 4
229920001436 collagen Polymers 0.000 description 4
230000015572 biosynthetic process Effects 0.000 description 3
239000003795 chemical substances by application Substances 0.000 description 3
230000037213 diet Effects 0.000 description 3
235000005911 diet Nutrition 0.000 description 3
210000003734 kidney Anatomy 0.000 description 3
239000000203 mixture Substances 0.000 description 3
125000001500 prolyl group Chemical group [H]N1C([H])(C(=O)[*])C([H])([H])C([H])([H])C1([H])[H] 0.000 description 3
238000003786 synthesis reaction Methods 0.000 description 3
RZVAJINKPMORJF-UHFFFAOYSA-N Acetaminophen Chemical compound CC(=O)NC1=CC=C(O)C=C1 RZVAJINKPMORJF-UHFFFAOYSA-N 0.000 description 2
CIWBSHSKHKDKBQ-JLAZNSOCSA-N Ascorbic acid Chemical compound OC[C@H](O)[C@H]1OC(=O)C(O)=C1O CIWBSHSKHKDKBQ-JLAZNSOCSA-N 0.000 description 2
102000004190 Enzymes Human genes 0.000 description 2
108090000790 Enzymes Proteins 0.000 description 2
238000000692 Student's t-test Methods 0.000 description 2
239000007853 buffer solution Substances 0.000 description 2
210000002808 connective tissue Anatomy 0.000 description 2
WEXRUCMBJFQVBZ-UHFFFAOYSA-N pentobarbital Chemical compound CCCC(C)C1(CC)C(=O)NC(=O)NC1=O WEXRUCMBJFQVBZ-UHFFFAOYSA-N 0.000 description 2
102000004169 proteins and genes Human genes 0.000 description 2
108090000623 proteins and genes Proteins 0.000 description 2
239000000243 solution Substances 0.000 description 2
101150039167 Bex3 gene Proteins 0.000 description 1
241000283690 Bos taurus Species 0.000 description 1
102000016938 Catalase Human genes 0.000 description 1
108010053835 Catalase Proteins 0.000 description 1
206010011416 Croup infectious Diseases 0.000 description 1
BWGNESOTFCXPMA-UHFFFAOYSA-N Dihydrogen disulfide Chemical compound SS BWGNESOTFCXPMA-UHFFFAOYSA-N 0.000 description 1
208000004930 Fatty Liver Diseases 0.000 description 1
206010016334 Feeling hot Diseases 0.000 description 1
206010019708 Hepatic steatosis Diseases 0.000 description 1
206010019728 Hepatitis alcoholic Diseases 0.000 description 1
235000008694 Humulus lupulus Nutrition 0.000 description 1
244000025221 Humulus lupulus Species 0.000 description 1
241000521257 Hydrops Species 0.000 description 1
102000008109 Mixed Function Oxygenases Human genes 0.000 description 1
108010074633 Mixed Function Oxygenases Proteins 0.000 description 1
241000699670 Mus sp. Species 0.000 description 1
206010030113 Oedema Diseases 0.000 description 1
241000283973 Oryctolagus cuniculus Species 0.000 description 1
ONIBWKKTOPOVIA-UHFFFAOYSA-N Proline Natural products OC(=O)C1CCCN1 ONIBWKKTOPOVIA-UHFFFAOYSA-N 0.000 description 1
229920002472 Starch Polymers 0.000 description 1
230000003187 abdominal effect Effects 0.000 description 1
230000002159 abnormal effect Effects 0.000 description 1
239000002253 acid Substances 0.000 description 1
239000004480 active ingredient Substances 0.000 description 1
230000007059 acute toxicity Effects 0.000 description 1
231100000403 acute toxicity Toxicity 0.000 description 1
208000002353 alcoholic hepatitis Diseases 0.000 description 1
229960005070 ascorbic acid Drugs 0.000 description 1
235000010323 ascorbic acid Nutrition 0.000 description 1
239000011668 ascorbic acid Substances 0.000 description 1
238000003556 assay Methods 0.000 description 1
239000002775 capsule Substances 0.000 description 1
150000001768 cations Chemical class 0.000 description 1
229920002678 cellulose Polymers 0.000 description 1
239000001913 cellulose Substances 0.000 description 1
238000006243 chemical reaction Methods 0.000 description 1
230000007882 cirrhosis Effects 0.000 description 1
208000019425 cirrhosis of liver Diseases 0.000 description 1
230000002596 correlated effect Effects 0.000 description 1
201000010549 croup Diseases 0.000 description 1
230000008021 deposition Effects 0.000 description 1
239000012153 distilled water Substances 0.000 description 1
208000010706 fatty liver disease Diseases 0.000 description 1
238000011534 incubation Methods 0.000 description 1
208000019423 liver disease Diseases 0.000 description 1
239000002075 main ingredient Substances 0.000 description 1
238000012986 modification Methods 0.000 description 1
230000004048 modification Effects 0.000 description 1
210000000056 organ Anatomy 0.000 description 1
229960001412 pentobarbital Drugs 0.000 description 1
230000002250 progressing effect Effects 0.000 description 1
239000011541 reaction mixture Substances 0.000 description 1
239000008107 starch Substances 0.000 description 1
235000019698 starch Nutrition 0.000 description 1
231100000240 steatosis hepatitis Toxicity 0.000 description 1
230000000638 stimulation Effects 0.000 description 1
239000000758 substrate Substances 0.000 description 1
238000012360 testing method Methods 0.000 description 1
210000001519 tissue Anatomy 0.000 description 1
238000005292 vacuum distillation Methods 0.000 description 1
XLYOFNOQVPJJNP-UHFFFAOYSA-N water Chemical compound O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 1

Classifications

- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/16—Amides, e.g. hydroxamic acids
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
- A61K31/19—Carboxylic acids, e.g. valproic acid
- A61K31/195—Carboxylic acids, e.g. valproic acid having an amino group

Landscapes

Health & Medical Sciences (AREA)
Animal Behavior & Ethology (AREA)
Medicinal Chemistry (AREA)
Pharmacology & Pharmacy (AREA)
Epidemiology (AREA)
Life Sciences & Earth Sciences (AREA)
Chemical & Material Sciences (AREA)
General Health & Medical Sciences (AREA)
Public Health (AREA)
Veterinary Medicine (AREA)
Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
Medicines Containing Plant Substances (AREA)
Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

PH38005A 1988-01-06 1989-01-05 Inhibitory agent of hepatic fibrosis PH26554A (en)

Applications Claiming Priority (1)

Application Number	Priority Date	Filing Date	Title
JP106788		1988-01-06

Publications (1)

Publication Number	Publication Date
PH26554A true PH26554A (en)	1992-08-19

Family

ID=11491185

Family Applications (1)

Application Number	Title	Priority Date	Filing Date
PH38005A PH26554A (en)	1988-01-06	1989-01-05	Inhibitory agent of hepatic fibrosis

Country Status (8)

Country	Link
US (1)	US4937266A (es)
EP (1)	EP0323855B1 (es)
KR (1)	KR970005324B1 (es)
AU (1)	AU614569B2 (es)
CA (1)	CA1318254C (es)
DE (1)	DE68914468T2 (es)
ES (1)	ES2054881T3 (es)
PH (1)	PH26554A (es)

Families Citing this family (10)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
JPH02232670A (ja) *	1989-03-06	1990-09-14	Minolta Camera Co Ltd	複写機
US5789426A (en) *	1995-01-20	1998-08-04	Cornell Research Foundation, Inc.	Method for the treatment of fibroproliferative disorders by application of inhibitors of protein hydroxylation
US6046219A (en) *	1995-01-20	2000-04-04	Cornell Research Foundation, Inc.	Method for the treatment of conditions mediated by collagen formation together with cell proliferation by application of inhibitors of protein hydroxylation
US5965621A (en) *	1995-08-17	1999-10-12	Allergan	Methods and compositions for reducing or maintaining body weight in a mammal
WO2002098405A1 (fr) *	2001-06-05	2002-12-12	Ajinomoto Co., Inc.	Inhibiteurs de fibrose du foie
WO2005089316A2 (en)	2004-03-12	2005-09-29	Intercept Pharmaceuticals, Inc.	Treatment of fibrosis using fxr ligands
EP3266782B1 (en)	2013-02-07	2019-10-30	SciFluor Life Sciences, Inc.	Fluorinated integrin antagonists
EP3925959A1 (en)	2015-02-19	2021-12-22	OcuTerra Therapeutics, Inc.	Fluorinated derivatives of 3-(2-oxo-3-(3-(5,6,7,8-tetrahydro-1,8-naphthyridin-2-yl)propyl)imidazolidin-1-yl)propanoic acid and uses thereof
JP2018514568A (ja)	2015-04-30	2018-06-07	サイフルーアライフサイエンシズインコーポレイテッド	テトラヒドロナフチリジニルプロピオン酸誘導体およびその使用法
US10118929B2 (en)	2016-04-27	2018-11-06	Scifluor Life Sciences, Inc.	Nonanoic and decanoic acid derivatives and uses thereof

Family Cites Families (1)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
GB2110536B (en) *	1981-12-04	1986-10-29	Sogo Pharm	Pharmaceutical compositions containing pantetheine-s-sulphonic acid

1988
- 1988-12-29 CA CA000587236A patent/CA1318254C/en not_active Expired - Fee Related
1989
- 1989-01-03 US US07/292,793 patent/US4937266A/en not_active Expired - Fee Related
- 1989-01-04 AU AU27723/89A patent/AU614569B2/en not_active Ceased
- 1989-01-05 EP EP89100180A patent/EP0323855B1/en not_active Expired - Lifetime
- 1989-01-05 PH PH38005A patent/PH26554A/en unknown
- 1989-01-05 KR KR1019890000030A patent/KR970005324B1/ko not_active Expired - Fee Related
- 1989-01-05 DE DE68914468T patent/DE68914468T2/de not_active Expired - Fee Related
- 1989-01-05 ES ES89100180T patent/ES2054881T3/es not_active Expired - Lifetime

Also Published As

Publication number	Publication date
AU614569B2 (en)	1991-09-05
AU2772389A (en)	1989-07-13
DE68914468T2 (de)	1994-07-28
EP0323855A3 (en)	1990-12-05
ES2054881T3 (es)	1994-08-16
CA1318254C (en)	1993-05-25
KR970005324B1 (ko)	1997-04-15
EP0323855A2 (en)	1989-07-12
DE68914468D1 (de)	1994-05-19
KR890011588A (ko)	1989-08-21
US4937266A (en)	1990-06-26
EP0323855B1 (en)	1994-04-13

Publication	Publication Date	Title
Janoff et al.	1962	Pathogenesis of experimental shock: IV. Studies on lysosomes in normal and tolerant animals subjected to lethal trauma and endotoxemia
Middeldorp et al.	2000	Effects on coagulation of levonorgestrel-and desogestrel-containing low dose oral contraceptives: a cross-over study
Valentine et al.	1957	The relationship of leukocyte alkaline phosphatase to “stress,” to ACTH, and to adrenal 17-OH-corticosteroids
Edwards et al.	1993	Nitric oxide‐related vasodilator responses to parasympathetic stimulation of the submandibular gland in the cat.
DE69530308D1 (de)	2003-05-15	Verfahren zur herstellung von dosierungsformen durch feuchtgranulierung
Boegman et al.	1992	Excitotoxic lesions of rat basal forebrain: differential effects on choline acetyltransferase in the cortex and amygdala
Lazarow et al.	1950	Protection against diabetes with nicotinamide
KIMBERLY	1982	Pulse methylprednisolone in SLE
ATE254847T1 (de)	2003-12-15	Verfahren zur identifikation von verbindungen, welche die bindenden wechselwirkungen zwischen den vpr und rip-1 proteinen von hiv-1 aufheben können
US4937266A (en)	1990-06-26	Inhibitory agent of hepatic fibrosis
Lee et al.	1983	Age-related changes in esterase activity in rabbit eyes
Debeer et al.	1977	Effect of sulfonylureas on triglyceride metabolism in the rat liver: possible role of the lysosomes in hepatic lipolysis.
ROBERTSON	1966	Serum cholinesterase deficiency I: disease and inheritance
Zawalich et al.	1991	Influence of staurosporine on glucose-mediated and glucose-conditioned insulin secretion
Wanders et al.	1990	First prenatal diagnosis of acyl‐CoA oxidase deficiency
Murphy	1966	Response of adaptive rat liver enzymes to acute poisoning by organophosphate insecticides
Neubert et al.	1974	Induction of skeletal malformations in organ cultures of mammalian embryonic tissues
Flitman et al.	1966	Inhibition of hepatic alcohol dehydrogenase by bilirubin
CA2388180A1 (en)	2001-05-10	Inhibitors of the inositol polyphosphate 5-phosphatase ship2 molecule
Dawson	1994	Rate constants of carbamylation and decarbamylation of acetylcholinesterase for physostigmine and carbaryl in the presence of an oxime
Kashfi et al.	1991	Malonyl-CoA inhibits proteolysis of carnitine palmitoyltransferase
Koppanyi et al.	1953	Correlation between pharmacological responses to benzoylcholine, methacholine and acetylcholine and activity of cholinesterases
Corrêa et al.	2001	Leiomyomatous hamartoma of the incisive papilla
Grodins et al.	1941	Observations on the toxicities and choleretic activities of certain bile salts
Hartung et al.	1968	Cholinesterase inhibition in the acute toxicity of alkyl-substituted 2-aminoethanols